Zhitong Finance App News, Yuekang Pharmaceutical (688658.SH) issued an announcement. Recently, Guangzhou Yuekang Biopharmaceutical Co., Ltd., a subsidiary of the company, received the “Drug Registration Certificate” approved by the State Drug Administration, and the company's new drug Zihuawen pulmonary cough tablets obtained marketing approval.

Zihuawen lung cough relief granules are class 1.1 of traditional Chinese medicine. The prescription of this drug is derived from clinical empirical formulations. It has the effect of warming the lungs and relieving cough, and is used for coughs with wind chills and lung symptoms. The marketing of this drug provides a new medication option for patients with wind chills, lung symptoms, and cough with a course of illness of 3 to 6 weeks.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.